tiprankstipranks
Analyst Profile
Followed by 277 other investors
.
Sarah James

Sarah James

Barclays
Wall Street Analyst
Ranked #476 out of 8,047 Analysts on TipRanks (#626 out of 21,521 overall experts)

Success Rate

68%
129 out of 189 Profitable Transactions

Average Return

13.20%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Sarah James's ratings since 2012 and opened each position for the duration of 1 Year:
68.25% of your transactions would have been profitable with an average return of 13.2%

Stock Rating Distribution

327Ratings
63.30% Buy
30.58% Hold
6.12% Sell
Distribution of Sarah James's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Progyny, Inc.
(PGNY)
Rating Type:Buy
Dates:Jul 09, 2020 - Jul 09, 2021
Gain:125.30%
The most profitable rating made by Sarah James

Sarah James's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
AmeriGroup
Hold
Downgraded
0.00%
1
Coventry Health Care
Hold
Upgraded
0.00%
1
Health Net
Hold
Reiterated
100%
+18.50%
3
Universal American
Hold
Reiterated
0.00%
5
Athenahealth
Buy
Reiterated
100%
+4.70%
1
Intuitive Surgical
Hold
Reiterated
$290.00
(21.66% Upside)
0.00%
1
LifePoint Health
Hold
Reiterated
0.00%
6
Aetna Inc
Hold
Downgraded
100%
+9.80%
11
Community Health
Sell
Reiterated
$3.00
(-19.79% Downside)
75%
+6.00%
12
Henry Schein
Buy
Reiterated
$80.00
(3.20% Upside)
80%
+5.00%
7
List of latest recommendations made by Sarah James. Click to expand and see Sarah James's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More